Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

LEVOMEFOLATE: 49 Adverse Event Reports & Safety Profile

Sharpen Your Memory & Focus Naturally

NeuroZoom — 35 clinically studied ingredients. No stimulants. Pure brain support.

Boost Your Brain
49
Total FAERS Reports
0
Deaths Reported
7
Hospitalizations
49
As Primary/Secondary Suspect
1
Life-Threatening
1
Disabilities
PureTek Corporation
Manufacturer

Active Ingredient: LEVOMEFOLATE CALCIUM · Route: ORAL · Manufacturer: PureTek Corporation · HUMAN PRESCRIPTION DRUG · FDA Label: Available

First Report: 1980 · Latest Report: 20240318

What Are the Most Common LEVOMEFOLATE Side Effects?

#1 Most Reported
Weight increased
6 reports (12.2%)
#2 Most Reported
Headache
6 reports (12.2%)
#3 Most Reported
Foetal exposure during pregnancy
6 reports (12.2%)

All LEVOMEFOLATE Side Effects by Frequency

Side Effect Reports % of Total Deaths Hosp.
Anxiety 6 12.2% 0 1
Drug ineffective 6 12.2% 0 0
Foetal exposure during pregnancy 6 12.2% 0 3
Headache 6 12.2% 0 1
Weight increased 6 12.2% 0 2
Drug hypersensitivity 5 10.2% 0 0

Who Reports LEVOMEFOLATE Side Effects? Age & Gender Data

Gender: 53.8% female, 46.2% male. Average age: 48.9 years. Most reports from: US. View detailed demographics →

Is LEVOMEFOLATE Getting Safer? Reports by Year

YearReportsDeathsHosp.
2009 1 0 1
2010 1 0 0
2012 1 0 0
2015 3 0 0
2016 4 0 1
2017 3 0 0
2018 1 0 0
2019 1 0 0
2020 5 0 0
2021 5 0 0
2022 1 0 0
2024 1 0 0

View full timeline →

What Is LEVOMEFOLATE Used For?

IndicationReports
Product used for unknown indication 16
Depression 5

Official FDA Label for LEVOMEFOLATE

Official prescribing information from the FDA-approved drug label.

Drug Description

DESCRIPTION Folixate ™ is an orally administered prescription folate product for the dietary management of patients with unique nutritional needs requiring increased folate level and Vitamin D supplementation due to Vitamin D deficiency. Folixate ™ should be administered under the supervision of a licensed healthcare practitioner. Each tablet contains: Folate (as L-5-Methyltetrahydrofolate calcium salt)......1700 mcg DFE (1000 mcg of L-5-methylfolate) Vitamin D3 (as Cholecalciferol)………....................125 mcg (5000 IU) Each tablet contains the following inactive ingredients: Lactose Monohydrate, Magnesium Stearate, Microcrystalline Cellulose, Sodium Starch Glycolate, Vegetable Stearic Acid.

FDA Approved Uses (Indications)

INDICATIONS AND USAGE Folixate ™ is indicated for dietary management of patients with unique nutritional needs requiring increased folate level and Vitamin D supplementation. Folixate™ can be taken by women of childbearing age, pregnant women, and lactating and nonlactating mothers.

Dosage & Administration

DOSAGE AND ADMINISTRATION Take one tablet daily or as directed by a licensed healthcare practitioner.

Contraindications

CONTRAINDICATIONS This product is contraindicated in patients with a known hypersensitivity to any of the ingredients. Folixate ™ is contraindicated in patients with hypercalcemia, malabsorption syndrome, abnormal sensitivity to the toxic effects of Vitamin D, and hypervitaminosis D.

Known Adverse Reactions

ADVERSE REACTIONS Allergic sensitization has been reported following both oral and parenteral administration of folate. You should call your doctor for medical advice about serious adverse events. To report adverse side effects or to obtain product information, contact PureTek Corporation, at 1-877-921-7873.

Warnings

WARNINGS AND PRECAUTIONS Tell your doctor if you have: kidney problems, thyroid disease. This medication should be used as directed during pregnancy or while breast-feeding. Consult your doctor about the risks and benefits. Folate alone is improper therapy in the treatment of pernicious anemia and other megaloblastic anemias where Vitamin B12 is deficient. Folate in doses above 0.1 mg daily may obscure pernicious anemia in that hematologic remission can occur while neurological manifestations progress.